Search clinical trials for: Rituximab 375

Total 5258 results

Dana-Farber Cancer Institute
Genentech, Inc.; Biogen

Completed

Rituximab for Prevention of Chronic GVHD

Hematological Malignancies

United States
University Hospital, Toulouse

Completed

Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab (PK-rituximab)

Autoimmune Diseases | Renal Transplant

France
University Hospital, Grenoble

Terminated

Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates

Kidney Transplantation | End-stage Renal Disease | Hla-incompatible Kidney Transplant Candidates

France
Stanford University

Completed

Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large Cell Lymphoma | Transformed Lymphoma | Other Subtypes of B-cell Lymphoma

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome (OBIRINS)

Steroid-Dependent Nephrotic Syndrome | Steroid-Sensitive Nephrotic Syndrome

France
Jurgen Barth

Completed

Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab

Hairy Cell Leukemia (HCL)

Germany
University of Giessen

Completed

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Germany
Optinose US Inc.

Recruiting

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

Bilateral Nasal Polyposis

United States
Optinose US Inc.

Completed

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

Chronic Rhinosinusitis

United States, United Kingdom, Bulgaria, Canada, Georgia, Poland, Russian Federation, Sweden
Optinose US Inc.

Completed

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

Chronic Rhinosinusitis

United States, Australia, Poland, New Zealand, Spain, Georgia, United Kingdom, Bulgaria, Czechia, Romania
Chong Kun Dang Pharmaceutical

Unknown

The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-375

Type 2 Diabetes Mellitus
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375

Type2 Diabetes Mellitus

Korea, Republic of
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Completed

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

Nonalcoholic Steatohepatitis (NASH)

China
Takeda

Completed

Efficacy of Ramelteon in Subjects With Chronic Insomnia

Sleep Initiation and Maintenance Disorders

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Grade 3a Follicular Lymphoma

United States
Seagen Inc.

Completed

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, T-Cell

United States, Canada
Takeda

Completed

The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy

Insomnia | Major Depressive Disorder

Japan
Takeda

Completed

Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and Healthy Adults

Insomnia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

EBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditions

United States
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
Celgene

Active, not recruiting

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Neoplasms

United States, France, Australia, Canada, Italy, Korea, Republic of, Spain, United Kingdom
Takeda

Completed

Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease

Chronic Insomnia

United States
Sohag University

Active, not recruiting

Clinical Outcomes of Post-placental Insertion of Cupper T380A and Multiload 375 Contraceptive Devices During Cesarean Section

IUD; Complications, Infection or Inflammation | IUD (Intrauterine Device) Malposition

Egypt
Groupe Oncologie Radiotherapie Tete et Cou
Tumor Study Group Head and Neck

Completed

Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation

Larynx Cancer | Hypopharynx Cancer

France
Northwestern University
Takeda

Terminated

Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism

Parkinsonism | REM Behavior Disorder

United States
Takeda

Completed

Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Chronic Insomnia

Insomnia

United States
Takeda

Completed

Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.

Chronic Insomnia

United States, Australia, France, Germany, Belgium, Finland, Russian Federation, Italy, Czech Republic
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditions

United States
Takeda

Completed

Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.

Chronic Insomnia

United States
Takeda

Terminated

Efficacy of Ramelteon in Adults With Chronic Insomnia

Chronic Insomnia

United States
Takeda

Completed

Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome

Sleep Disorders, Circadian Rhythm

United States
Takeda

Completed

Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia

Chronic Insomnia

United States, Canada
Takeda

Completed

Efficacy of Ramelteon on Transient Insomnia in Healthy Adults

Transient Insomnia

United States
Takeda

Completed

Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia

Sleep Initiation and Maintenance Disorders
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia

United States
Takeda

Completed

Ramelteon in Adults With Chronic Insomnia

Chronic Insomnia

United States
Takeda

Completed

Study of Efficacy of Ramelteon in Adults With Chronic Insomnia

Chronic Insomnia

United States
Takeda

Completed

Safety and Efficacy of Ramelteon in Healthy Subjects

Sleep Disorder

United States
Takeda

Completed

Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers

Circadian Dysregulation

United States
Apnimed

Completed

AD109 Dose Finding in Mild to Moderate OSA

Obstructive Sleep Apnea

United States
National Cancer Institute (NCI)
Celgene Corporation

Active, not recruiting

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
Pfizer

Completed

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Rheumatoid Arthritis

United States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
Mabion SA
Parexel

Withdrawn

MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis (MABRIDGE)

Rheumatoid Arthritis
Takeda

Completed

Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
National Cancer Institute (NCI)

Active, not recruiting

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma

United States
Northwestern University
Seagen Inc.

Terminated

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell... and other conditions

United States
Takeda

Completed

Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea

Sleep Apnea, Obstructive

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States

Search clinical trials for: Rituximab 375

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations